Researchers identify a protein that may predict who will have thyroid cancer recurrence

October 8, 2013

Researchers at the National Institutes of Health (NIH), Bethesda, MD, have taken the first steps to determine if a protein, called Programmed Death Ligand 1 (PD-L1), can help to predict which thyroid cancer patients will most likely have a recurrence of the disease. Study findings were presented today at the 2013 Clinical Congress of the American College of Surgeons.

More than 80 percent of diagnosed with have a type called papillary thyroid cancer, which usually grows on only one side of the thyroid gland, according to the American Cancer Society.1 Most of these patients are women and some have been exposed to ionizing radiation, reports the Centers for Disease Control and Prevention.2

Although the five-year survival rate is 93 percent at stage three,3 the number of people diagnosed with papillary thyroid cancer each year has more than doubled in the last 25 years to 60,220, the American Cancer Society reports.4 Although thyroid cancer is not usually aggressive, the National Cancer Institute estimates that 10 to 30 percent of these patients still end up having a recurrence.5

Previous research has already shown a connection between papillary thyroid cancer and the through inflammatory thyroid disease, reports study coauthor Ryan J. Ellis, a researcher in the endocrine oncology branch of the NIH and a fourth-year medical student at the University of Pennsylvania's Perelman School of Medicine.

This NIH study specifically focused on the role of a specific protein, PD-L1, which is normally present in the body's immune system to assist with communication between immune cells and help regulate immune response. PD-L1 is also present in some papillary thyroid cancer cells, and may actually help to protect the tumor from the immune system.

"If the immune system tries to approach the tumor and its immediate surrounding area, PD-L1 will make the immune system take a step back and turn off," Mr. Ellis explained.

This protection may then allow the cancer to grow and eventually spread, often to the .

Focusing on prognosis

For other types of cancer, previous clinical trials have used certain treatments to block PD-L1 on the cancerous tumor, allowing the immune system to infiltrate and attack the cancer, explained Myriem Boufraqech, PhD, study coauthor and researcher in the endocrine oncology branch of the NIH. However,

Dr. Boufraqech, Mr. Ellis, and their colleagues wanted to deter-mine the role that PD-L1 plays in predicting whether patients have a more aggressive form of papillary thyroid cancer.

For this study, the researchers looked at resected tumor samples from more than 200 patients. The samples had been stored at extreme freezing temperatures, about negative 80 degrees Celsius. They then used gene expression microarrays to collect data on more than 30,000 genes in each sample—including the PD-L1 gene.

Next, the investigators were able to confirm these findings by focusing on PD-L1 expression in each sample. The final step was to compare PD-L1 levels with medical records of how the patients fared.

"In this cohort of patients, we found that those with high levels of PD-L1 were about twice as likely to have a recurrence as patients with normal PD-L1 levels," Mr. Ellis reported. Results also showed that higher levels of PD-L1 were associated with a higher tendency of having the cancer spread to the lymph nodes.

Next steps and ultimate goals

Mr. Ellis explained that this study is still too early and the cohort group is too small to say whether PD-L1 is associated with a higher likelihood of dying from papillary thyroid cancer, mainly because the number of people who die from the disease is very low.

"This is the first study to show a specific function of the immune system in the proliferation of thyroid cancer," said Lisa Zhang, PhD, study coauthor and a researcher in the endocrine oncology branch of the NIH.

As the study moves from data analysis into a mouse model and ultimately to clinical trials, Mr. Ellis said the findings could potentially change how surgeons provide care to patients before and after their cancer operations. "The real potential is being able to differentiate, by the time of surgical treatment, who may have a more aggressive type of thyroid cancer," Mr. Ellis said. "Surgeons could potentially look at the patient's PD-L1 expression following biopsy or immediately after resection to see if the patient is more likely to have a recurrence."

"That approach could change the course of treatment," he added, "and allow surgeons, medical endocrinologists, and oncologists to more intelligently make postoperative decisions for their patients that would help to reduce the risk of a ." Electron Kebebew, MD, FACS, also participated in this study.

Explore further: Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas

More information: 1 "What is Thyroid Cancer?" American Cancer Society. Available at: American Cancer Society. Accessed: September 10, 2013.

2 "Thyroid Cancer and the Environment." Centers for Disease Control and Prevention. Available at: U.S. Centers for Disease Control and Prevention. Accessed: September 10, 2013.

3 "Thyroid cancer survival by type and stage." American Cancer Society. … ancer-survival-rates (.) Accessed: September 10, 2013.

4 "What are the key statistics about thyroid cancer?" American Cancer Society. … ancer-key-statistics (.)

Accessed: September 10, 2013.

5 " Recurrent Thyroid Cancer." National Cancer Institute. … rofessional/page9(.) Accessed: September 10, 2013.

Related Stories

Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas

May 28, 2013
Sarcomatoid carcinomas of the lung include rare subtypes of poorly differentiated non–small-cell lung carcinomas of high grade and aggressive behavior. The biology of these neoplasms is poorly understood and these tumors ...

Promising results for new antibody drug in non-small cell lung cancer patients: Smokers respond well

September 30, 2013
New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.

Promising drug prevents cancer cells from shutting down immune system

June 4, 2013
(Medical Xpress)—An investigational drug that targets the immune system's ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients with a variety of advanced or metastatic forms of the disease. ...

Engineered antibody demonstrated safety, efficacy in wide range of advanced tumors

April 10, 2013
(Medical Xpress)—The engineered antibody MPDL3280A, which targets a protein called programmed death-ligand 1 (PD-L1), was safe and effective for several cancers, according to phase I study results presented at the AACR ...

Familial component identified in papillary thyroid cancer

October 7, 2013
(HealthDay)—First-degree, second-degree, and third-degree relatives of patients diagnosed with papillary thyroid cancer (PTC) are at significantly increased risk of developing the disease, according to research published ...

Cancer therapy that boosts immune system ready for wider testing

June 2, 2012
Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have ...

Recommended for you

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.